SCHEMBL1745549

SCHEMBL1745549

CCC(C(=O)O)N(CC)CC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.32
HTR2A P28223 2/20 0.32
HRH1 P35367 2/20 0.32
PGR P06401 1/20 0.32
ADRA2B P18089 1/20 0.32
KCNH2 Q12809 1/20 0.32
FDPS P14324 1/20 0.32
TDP1 Q9NUW8 3/20 0.32
EYA2 O00167 1/20 0.32
APP P05067 1/20 0.32
ACE P12821 1/20 0.32
FFAR3 O14843 1/20 0.32
ADRA1A P35348 2/20 0.31
DRD3 P35462 2/20 0.31
SLC6A3 Q01959 2/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
CHRM2 P08172 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL957226 0.91 FFAR3 (0.35) ADRA2AHTR2AHRH1TDP1EYA2
SCHEMBL215964 0.91 FFAR3 (0.35) ADRA2AHTR2AHRH1TDP1EYA2
SCHEMBL155767 0.86 FDPS (0.37) ADRA2AHTR2AHRH1PGRADRA2B
SCHEMBL19886164 0.86 FDPS (0.37) ADRA2AHTR2AHRH1PGRADRA2B
SCHEMBL3785080 0.86 FDPS (0.37) ADRA2AHTR2AHRH1PGRADRA2B
Glycine SCHEMBL8537150 0.83 GLRA1 (0.30)
Acetamide SCHEMBL5961960 0.82 LMNA (0.31) LMNAALOX15BLMPMP22
SCHEMBL5177311 0.82 TDP1 (0.33) ADRA2ATDP1EYA2APPACE
SCHEMBL29016771 0.82 HTR2A (0.31) ADRA2AHTR2AHRH1PGRADRA2B
SCHEMBL8825871 0.80 TDP1 (0.52) ADRA2ATDP1EYA2APPACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432846-B1 NOVEL FORMULATIONS OF WATER-SOLUBLE POLYMERS AND STABILIZING ADDITIVES FOR INJECTING A SINGLE COMPOUND USEABLE IN INJECTION FLUIDS FOR CHEMICAL ENHANCED OIL RECOVERY SPCM SA (FR) 2019-05-01 EP claimed
EP-1737899-B1 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES INC (US) 2015-07-08 EP claimed
EP-2385078-A1 Dendritic polymers with enhanced amplification and interior functionality Dendritic Nanotechnologies Inc. (US) 2011-11-09 EP claimed
US-20110254461-A1 Power adaptors HOLDIP LIMITED (GB) 2011-10-20 US claimed
US-7985424-B2 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES INC. (US) 2011-07-26 US claimed
US-7981444-B2 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2011-07-19 US claimed
EP-2325236-A1 Dendritic polymers with enhanced amplification and interior functionality Dendritic Nanotechnologies Inc. (US) 2011-05-25 EP claimed
JP-2008545621-A 2008-12-18 JP claimed
EP-1737899-A4 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES INC (US) 2008-03-05 EP claimed
EP-1877103-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY Dendritic Nanotechnologies, Inc. (US) 2008-01-16 EP claimed
US-20070298006-A1 Dendritic Polymers With Enhanced Amplification and Interior Functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2007-12-27 US claimed
US-20070244296-A1 Dendritic Polymers with Enhanced Amplification and Interior Functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2007-10-18 US claimed
EP-1737899-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY Dendritic Nanotechnologies, Inc. (US) 2007-01-03 EP claimed
WO-2006065266-A9 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES INC (US) 2006-12-21 WO claimed
WO-2006115547-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES, INC. (US) 2006-11-02 WO claimed
WO-2006065266-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES, INC. (US) 2006-06-22 WO claimed
US-4581221-A TECHNETIUM LABELLED CARRIER REACTED WITH AN ULCER SPECIFIC OLIGOSACCHARIDE SULFATE MEDI NUCLEAR CORPORATION, INC. (US) 1986-04-08 US claimed
US-4117225-A ANTICONVULSANTS G.D. SEARLE & CO. (US) 1978-09-26 US claimed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
US-4117225-A ANTICONVULSANTS G.D. SEARLE & CO. (US) 1978-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070298006-A1 Dendritic Polymers With Enhanced Amplification and Interior Functionality MYD88, TLR3, TMEM97 ADRA2A 677/4885HTR2A 2325/4885HRH1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.